Clinical-stage biotech developing oral small-molecule GLP-1 drugs for obesity and metabolic disease.
Clinical-stage biotech developing oral small-molecule GLP-1 drugs for obesity and metabolic disease.
Has no approved product and no partner revenue, so it is funded by selling shares to investors. Its research is split between South San Francisco and Shanghai. The case for its drug is a daily pill that avoids the injections used by most weight-loss drugs today.
Moat: none (IP / patents). Pre-commercial; competing against well-funded incumbents in the crowded oral GLP-1 obesity race.
Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 220
Size Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.24B, the 2097th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.36 on 18 Nov 2026.
Performance Over six months the shares fell 52.9%, against -20.6% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Short interest Short interest is 8.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$4.74M | -$3.90M | -$2.60M | -$949,174 | -$623,259 |
| EBITDA | -$447M | -$284M | -$156M | -$102M | -$51.9M |
| Net income | -$295M | -$142M | -$123M | -$89.5M | -$51.3M |
| Free cash flow | -$278M | -$226M | -$118M | -$81.6M | -$46.2M |
| Capital expenditure | $6.30M | $3.62M | $1.29M | $2.17M | $154,816 |
| Total debt | $6.83M | $6.49M | $3.86M | $5.45M | $260,001 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Structure Therapeutics, Inc. Sponsored ADR GPCR | $1.24B | -53% | n/a | n/a | n/a | n/a |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
| Viking Therapeutics VKTX | $3.34B | -9% | n/a | n/a | n/a | n/a |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GPCR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.1% | -5.1% | lowest of 21 |
| 6-month return | -52.9% | -20.6% | lowest of 21 |
| Distance from 52-week high | -81.7% | -41.7% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |